Californian aging specialist CohBar (Nasdaq: CWBR) is using mitochondrial science to treat diseases, but chief executive Steven Engle doesn’t rule out offering a “cure for aging” at some point.
Asked whether the firm could find itself developing products for healthy people to take, with the specific purpose of extending healthy lifespan, he says: “Yes, I think that's possible.”
He points to the example of metformin, a commonly used compound for diabetics, which he says “actually has positive effects on things like cancer.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze